Xin Lang Cai Jing·2026-03-31 07:34Core Viewpoint - Tiger Med's stock rose by 2.18% on March 31, with a trading volume of 1.167 billion yuan and a market capitalization of 46.349 billion yuan [1][10]. Group 1: Company Overview - Hangzhou Tiger Med Technology Co., Ltd. specializes in providing comprehensive clinical trial services for new drug development as a Contract Research Organization (CRO) [2][11]. - The company offers a range of services including clinical operations, clinical pharmacology, regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party audits, data management, and statistical analysis [2][11]. - Tiger Med has established itself as a leading CRO in China, focusing on clinical research services for both domestic and international pharmaceutical and health-related products, covering phases I to IV of clinical trials [2][12]. Group 2: Strategic Partnerships and Developments - In July 2018, Tiger Med signed a strategic cooperation agreement with Jiuzhou Pharmaceutical, a leading CDMO service provider, to collaborate in the clinical research and development of innovative drugs [2][12]. - The subsidiary, Jietong Tairui, focuses on providing clinical research outsourcing services for medical devices, including registration and clinical trial services [2][12]. Group 3: Clinical Trials and Research - In 2023, the company initiated its first Phase I clinical trial for a herpes zoster protein vaccine in the U.S. and a Phase III trial for a quadrivalent meningococcal vaccine in Indonesia, enrolling over 1,400 participants [3][11]. - Tiger Med completed two large-scale Phase III efficacy studies for vaccines in collaboration with the Chinese Center for Disease Control and Prevention, with a total enrollment exceeding 38,000 participants [3][11]. Group 4: Technological Innovations - The subsidiary, Taiya Technology, developed an AI product platform for medical applications based on the open-source model Qwen2.5, providing solutions for new drug development, clinical trials, and registration [4][13]. - The AI platform has achieved excellent scores across five MedBench evaluation dimensions, including medical language understanding and generation, and is designed to enhance medical translation and knowledge inquiry [4][13]. Group 5: Financial Performance - For the year 2025, Tiger Med reported a revenue of 6.833 billion yuan, representing a year-on-year growth of 3.48%, and a net profit attributable to shareholders of 888 million yuan, up 119.15% [8][19]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan in the last three years [9][19].